Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients
Richard S. P. Huang et al.
CLINICAL CHEMISTRY (2021)
Comparative landscape of actionable somatic alterations in advanced cholangiocarcinoma from circulating tumor and tissue-based DNA profiling.
Pashtoon Murtaza Kasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2021)
MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
P. Mack et al.
Journal of Thoracic Oncology (2021)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L. Tan et al.
ANNALS OF ONCOLOGY (2019)
Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor
Lena A. von Schuckmann et al.
JAMA DERMATOLOGY (2019)
Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Kezhong Chen et al.
CLINICAL CANCER RESEARCH (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
O. Michielin et al.
ANNALS OF ONCOLOGY (2019)
ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
Rakel Brendsdal Forthun et al.
SCIENTIFIC REPORTS (2019)
Time trends in incidence and mortality of cutaneous melanoma in Germany
C. Garbe et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Ashleigh C. McEvoy et al.
BMC CANCER (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
J. H. Lee et al.
ANNALS OF ONCOLOGY (2017)
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Ademi Santiago-Walker et al.
CLINICAL CANCER RESEARCH (2016)
Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Liqiang Xi et al.
CLINICAL CANCER RESEARCH (2016)
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Elin S. Gray et al.
ONCOTARGET (2015)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
